As the fight against COVID-19 continues, the use of CAR-T or TCR-T therapies may be able to help treat patients infected, but more research is needed.
The last decade of research has provided significant advances in anti-cancer immunotherapies. Particularly, the development of genetically modified T-cells has been successful in treating various types of cancers. Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy are major examples of highly studied immunotherapies. CAR-T cells recognize proteins or antigens expressed on the surface of cancer cells, whereas TCR-T cells recognize tumor antigens inside the cells.